Researchers have identified how to encourage tumors to build their own immune hubs—structures that look and function like ...
DuoCAR20.19.22-D95 targets CD19, CD20, and CD22, addressing antigen escape in B-cell malignancies like B-ALL and B-NHL. Early ...
A “complete eradication” of B cells with chimeric antigen receptor T-cell therapy is responsible for the long-term, drug-free remission from autoimmune diseases observed after treatment, according to ...
In vivo CD19 CAR T-cell therapy showed promising results in a feasibility study of five patients with refractory systemic ...
MedPage Today on MSN
Ulcerative Colitis: Next Target for CAR T-Cell Therapy?
The range of autoimmune diseases treatable with chimeric antigen receptor (CAR) T-cell therapy could be much broader than ...
CD19-targeting UB-VV11 became the first in vivo CAR-T cell therapy to be cleared for human testing by the FDA last year, and ...
About 30 percent of all non-Hodgkin lymphoma diagnoses in the United States are DLBCL. Although it is an aggressive cancer that can spread quickly, it is treatable. These can be symptoms of many ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback